Nektar Therapeutics (NKTR) Forms $85.18 Double Top; Enzo Biochem Has 1.24 Sentiment

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $301.50 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

Nektar Therapeutics (NKTR) formed double top with $91.99 target or 8.00% above today’s $85.18 share price. Nektar Therapeutics (NKTR) has $13.66B valuation. The stock decreased 1.59% or $1.38 during the last trading session, reaching $85.18. About 332,232 shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since March 1, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

The stock increased 1.50% or $0.095 during the last trading session, reaching $6.425. About 52,368 shares traded. Enzo Biochem, Inc. (ENZ) has risen 44.32% since March 1, 2017 and is uptrending. It has outperformed by 27.62% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 5 insider sales for $1.71 million activity.

Kopp Investment Advisors Llc holds 1.59% of its portfolio in Enzo Biochem, Inc. for 165,727 shares. Berson & Corrado Investment Advisors Llc owns 238,726 shares or 1.41% of their US portfolio. Moreover, Millrace Asset Group Inc. has 1.17% invested in the company for 119,238 shares. The Maryland-based Marathon Capital Management has invested 1.11% in the stock. First Light Asset Management Llc, a Minnesota-based fund reported 225,616 shares.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 EPS, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $80.0 highest and $16 lowest target. $38.29’s average target is -55.05% below currents $85.18 stock price. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. Piper Jaffray maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Thursday, January 7. Piper Jaffray has “Overweight” rating and $20.0 target. The rating was maintained by Roth Capital with “Buy” on Thursday, July 20. The firm earned “Buy” rating on Wednesday, August 16 by Jefferies. The rating was maintained by Canaccord Genuity on Wednesday, January 10 with “Buy”. The firm has “Buy” rating given on Monday, November 13 by Roth Capital. The firm has “Buy” rating by Roth Capital given on Tuesday, May 30. Jefferies maintained it with “Buy” rating and $35.0 target in Wednesday, November 8 report. The rating was initiated by Aegis Capital with “Buy” on Tuesday, November 8. The rating was maintained by Roth Capital on Monday, September 21 with “Buy”. The stock has “Buy” rating by Aegis Capital on Monday, June 5.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: